Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionKovack Advisors, Inc.
Latest Disclosed Ownership741 shares
Latest Disclosed Value $ 573,984
Kovack Advisors, Inc. reports 47.90% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 12, 2026 - Kovack Advisors, Inc. filed a 13F-HR form disclosing ownership of 741 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $573,984 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 17, 2026 disclosing 501 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 47.90% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 741 240 47.90 574 48.45 0.0306
2026-02-17 2025-12-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 501 118 30.81 387 79.53 0.0180
2026-02-12 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 501 118 342
2025-11-10 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 383 383 216 0.0203
2025-08-04 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -333 -100.00 0 -100.00
2025-05-06 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 333 11 3.42 211 -7.86 0.0224
2025-02-05 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 322 0 0.00 229 -32.25 0.0225
2024-11-05 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 322 -10 -3.01 338 -2.87 0.0359
2024-08-05 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 332 0 0.00 349 9.09 0.0384
2024-04-19 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 332 0 0.00 320 9.62 0.0387
2024-02-02 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 332 -3 -0.90 292 5.82 0.0346
2023-10-19 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 335 6 1.82 276 16.53 0.0385
2023-07-21 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 329 -51 -13.42 236 -24.36 0.0303
2023-04-21 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 380 55 16.92 312 33.33 0.0426
2023-02-22 2022-12-31 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 325 -10 -2.99 234 1.30 0.0343
2022-11-14 2022-09-30 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 335 -799 -70.46 231 -65.52 0.0339
2022-08-10 2022-06-30 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 1,134 -521 -31.48 670 -41.99 0.0884
2022-05-16 2022-03-31 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 1,655 282 20.54 1,155 33.22 0.1186
2022-01-18 2021-12-31 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 1,373 -108 -7.29 867 -3.24 0.0838
2021-11-03 2021-09-30 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 1,481 1,086 274.94 896 305.43 0.0974
2021-07-29 2021-06-30 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 395 395 221 0.0252
2020-11-02 2020-09-30 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 0 -365 -100.00 0 -100.00
2020-07-31 2020-06-30 13F REGENERON PHARMACEUTICALS ORD ORD 75886F107 365 365 228 0.0444
2019-08-14 2019-06-30 13F REGENERON PHARMACEUTICALS COM COM 75886F107 0 -556 -100.00 0 -100.00
2019-05-03 2019-03-31 13F REGENERON PHARMACEUTICALS COM COM 75886F107 556 556 228 0.0569
2019-02-06 2018-12-31 13F REGENERON PHARMACEUTICALS COM COM 75886F107 0 -511 -100.00 0 -100.00
2018-10-09 2018-09-30 13F REGENERON PHARMACEUTICALS COM COM 75886F107 511 -230 -31.04 206 -19.53 0.0531
2018-08-01 2018-06-30 13F REGENERON PHARMACEUTICALS COM COM 75886F107 741 -255 -25.60 256 -25.36 0.0715
2018-05-15 2018-03-31 13F REGENERON PHARMACEUTICALS COM COM 75886F107 996 199 24.97 343 14.33 0.0861
2018-05-15 2017-12-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 797 -320 -28.65 300 -39.88 0.0758
2018-02-01 2017-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 822 309
2018-08-02 2017-09-30 13F REGENERON PHARMACEUTICALS COM COM 75886F107 1,117 20 1.82 499 -7.42 0.1655
2018-08-30 2017-06-30 13F REGENERON PHARMACEUTICALS COM COM 75886F107 1,097 -1,279 -53.83 539 -41.48 0.1701
2018-09-05 2017-03-31 13F REGENERON PHARMACEUTICALS COM COM 75886F107 2,376 1,424 149.58 921 163.90 0.3586
2018-09-10 2016-12-31 13F REGENERON PHARMACEUTICALS COM COM 75886F107 952 952 349 0.1661
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.